Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the company’s abstract featuring clinical trial ...

ATM Pathway Inhibitor An investigational ATM pathway inhibitor has shown preliminary activity in combination with radiotherapy in patients with glioblastoma, according to a phase 0/Ib study.

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for ... gene mutation – including BRCA1/2 and ATM. If Pfizer gets FDA approval on ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

ATM-mediated TPX2 S634 phosphorylation is required for M-phase ... are indeed more vulnerable to DNA-damaging treatments.2–4 Recently, PARP inhibitors (PARPi) have shown promising synthetic lethality ...

The continuous interference of endogenous and external stressors during cell division and proliferation can cause DNA damage, which sets off DNA damage responses, activates ATM/ATR and other ... For ...

Managing hypertension (high blood pressure) before, during, and after surgery is important to ensuring the best outcomes. If your blood pressure is too high before surgery, the procedure may need to ...